AbbVie Raises Full-Year Guidance as Non-GAAP EPS Beats Estimates

AbbVie raised its full-year guidance after third-quarter revenue and non-GAAP earnings per share beat estimates, with its immunology portfolio also posting higher global net revenue. Revenue totaled $17.4 billion, up 10.3% from a year earlier and $50 million above estimates. Non-GAAP earnings per share was $3.82, exceeding estimates by $0.05. The immunology portfolio generated $9.165 billion in global net revenue during the quarter, a 16.3% increase on a reported basis. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Source: TokenPost